BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36965085)

  • 21. Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women.
    Aro K; Nieminen P; Louvanto K; Jakobsson M; Virtanen S; Lehtinen M; Dillner J; Kalliala I
    Gynecol Oncol; 2019 Aug; 154(2):354-359. PubMed ID: 31176553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Falcaro M; Castañon A; Ndlela B; Checchi M; Soldan K; Lopez-Bernal J; Elliss-Brookes L; Sasieni P
    Lancet; 2021 Dec; 398(10316):2084-2092. PubMed ID: 34741816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
    Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
    Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
    [No Abstract]   [Full Text] [Related]  

  • 24. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.
    Cameron RL; Kavanagh K; Cameron Watt D; Robertson C; Cuschieri K; Ahmed S; Pollock KG
    J Epidemiol Community Health; 2017 Oct; 71(10):954-960. PubMed ID: 28756395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
    Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
    Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
    Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
    Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.
    Hu SY; Kreimer AR; Porras C; Guillén D; Alfaro M; Darragh TM; Stoler MH; Villegas LF; Ocampo R; Rodriguez AC; Schiffman M; Tsang SH; Lowy DR; Schiller JT; Schussler J; Quint W; Gail MH; Sampson JN; Hildesheim A; Herrero R;
    J Natl Cancer Inst; 2022 Sep; 114(9):1253-1261. PubMed ID: 35640980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of HPV and pathological changes among women 70 years of age, 10 years after exclusion from the Swedish cervical cancer screening program.
    Bergengren L; Karlsson MG; Helenius G
    Cancer Causes Control; 2020 Apr; 31(4):377-381. PubMed ID: 32076907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical value of p16
    Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
    [No Abstract]   [Full Text] [Related]  

  • 32. Cervical Intraepithelial Neoplasia Rates in British Columbia Women: A Population-Level Data Linkage Evaluation of the School-Based HPV Immunization Program.
    Racey CS; Albert A; Donken R; Smith L; Spinelli JJ; Pedersen H; de Bruin P; Masaro C; Mitchell-Foster S; Sadarangani M; Dawar M; Krajden M; Naus M; van Niekerk D; Ogilvie G
    J Infect Dis; 2020 Jan; 221(1):81-90. PubMed ID: 31504649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study.
    Velentzis LS; Sitas F; O'Connell DL; Darlington-Brown J; Egger S; Sinha R; Banks E; Frazer IH; Canfell K
    BMC Infect Dis; 2014 Dec; 14():3861. PubMed ID: 25528152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The difference in the effectiveness of human papillomavirus vaccine based on smoking status.
    Hikari T; Honda A; Hashiguchi M; Okuma R; Kurihara M; Fukuda A; Okuma E; Nakao Y; Yokoyama M
    J Obstet Gynaecol Res; 2022 Jul; 48(7):1859-1866. PubMed ID: 35599387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination?
    Sultana F; Winch K; Saville M; Brotherton JML
    Int J Cancer; 2019 Jun; 144(12):2964-2971. PubMed ID: 30536935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
    Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
    JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
    Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.
    Lee GY; Inthasorn P; Laowahutanont P; Lawpoolsri S; Kamolratanakul S; Lungchukiet P; Oh J; Termrungruanglert W; Taechakraichana N; Pitisuttithum P
    Vaccine; 2022 Mar; 40(13):1968-1976. PubMed ID: 35190207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis.
    Ogembo RK; Gona PN; Seymour AJ; Park HS; Bain PA; Maranda L; Ogembo JG
    PLoS One; 2015; 10(4):e0122488. PubMed ID: 25875167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.